Welcome back,

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC

23 Jun 2022

Share

NON-SMALL CELL LUNG CANCER

Login

Get access to our exclusive articles.

Related articles

CONFERENCE UPDATE

AI-assisted screening detects early-stage lung cancer in high-risk never-smokers: Interim results from the local LC-SHIELD study
CONFERENCE UPDATE

SEER-MHOS analysis supports the use of local estrogen therapy in breast cancer patients
CONFERENCE UPDATE

Encorafenib + cetuximab + chemotherapy improves PFS and OS as first-line therapy in BRAF V600E-mutant mCRC: Results from the phase 3 BREAKWATER trial
CONFERENCE UPDATE

Nivolumab + chemotherapy improves long-term survival outcomes in resectable NSCLC: Final OS analysis from the CheckMate 816 trial
CONFERENCE UPDATE

Savolitinib + osimertinib prolongs PFS in METamp, EGFR-mutated NSCLC post-first-line EGFR TKI failure: Results from the phase 3 SACHI trial